ReviewVaccines2024
The Problem with Delaying Measles Elimination.
Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Beyond elimination: reframing measles vaccination strategies.BMJ global health · 2026Article
- The well-worn path from armed conflict to measles resurgence.PLoS medicine · 2026Article
- Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape.Vaccines · 2026Article
- Measles-rubella surveillance and its facilitators and barriers in Bagmati province, Nepal: a mixed methods study.BMC infectious diseases · 2026Article
- Recent Advances in Strategies Against Measles Spread: Clinical and Epidemiological Aspects, Impact, Vaccine Innovations, and Sustainable Recommendations.TheScientificWorldJournal · 2026Review
- Susceptibility of Measles Virus to World Health Organization-Recommended Hand Rubs, Oral Rinses, and Surface Disinfectants.Open forum infectious diseases · 2025Article
- Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Vaccination Status and Incidences of Measles, Mumps, and Rubella - Worldwide, 2014-2023.China CDC weekly · 2025Article
- Measles Vaccination Coverage and Anti-Measles Herd Immunity Levels in the World and WHO Regions Worsened from 2019 to 2023.Vaccines · 2025Article
- Progress Toward Measles Elimination - Worldwide, 2000-2023.MMWR. Morbidity and mortality weekly report · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Measles is a highly infectious disease leading to high morbidity and mortality impacting people's lives and economies across the globe. The measles vaccine saves more lives than any other vaccine in the Essential Programme of Immunization and is also the most cost-effective vaccine, with an extremely high return on investment. This makes achieving measles elimination through vaccination a key child health intervention, particularly in low-income countries, where the overwhelming majority of measles deaths continue to occur. All countries and regions of the world have committed to achieving measles elimination, yet many have faced challenges securing political commitment at national and global levels and predictable, timely, and flexible support from global donors, and experienced setbacks during the COVID-19 pandemic. This has happened against a backdrop of stagnant measles vaccination coverage and declining enthusiasm for vertical programmes, culminating in a World Health Organization Strategic Advisory Group of Experts (WHO SAGE) review of the feasibility of measles eradication in 2019. Sustaining the elimination of measles long term is extremely difficult, and some countries have lost or nearly lost their measles elimination status in the face of ongoing importation of cases from neighbouring or closely connected countries in which elimination had been delayed. Thus, a widening equity gap in measles immunisation coverage creates challenges for all countries, not just those facing the greatest burden of measles morbidity and mortality. Delaying elimination of measles in some countries makes it cumulatively harder for all countries to succeed for three principal reasons: increased inequity in measles immunisation coverage makes outbreaks more likely to happen and to be larger; political will is very difficult to sustain; and immunity may wane to a point that transmission is re-established. New strategies are needed to support countries and regions in their vision for a world without measles, including ways to galvanise domestic, regional and global resources and ignite the political will that is essential to make the vision a reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.